The epidemiology of drug use disorders cross-nationally: Findings from the WHO's World Mental Health Surveys.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
09 2019
Historique:
received: 26 10 2018
revised: 08 03 2019
accepted: 19 03 2019
pubmed: 1 7 2019
medline: 8 5 2020
entrez: 1 7 2019
Statut: ppublish

Résumé

Illicit drug use and associated disease burden are estimated to have increased over the past few decades, but large gaps remain in our knowledge of the extent of use of these drugs, and especially the extent of problem or dependent use, hampering confident cross-national comparisons. The World Mental Health (WMH) Surveys Initiative involves a standardised method for assessing mental and substance use disorders via structured diagnostic interviews in representative community samples of adults. We conducted cross-national comparisons of the prevalence and correlates of drug use disorders (DUDs) in countries of varied economic, social and cultural nature. DSM-IV DUDs were assessed in 27 WMH surveys in 25 countries. Across surveys, the prevalence of lifetime DUD was 3.5%, 0.7% in the past year. Lifetime DUD prevalence increased with country income: 0.9% in low/lower-middle income countries, 2.5% in upper-middle income countries, 4.8% in high-income countries. Significant differences in 12-month prevalence of DUDs were found across country in income groups in the entire cohort, but not when limited to users. DUDs were more common among men than women and younger than older respondents. Among those with a DUD and at least one other mental disorder, onset of the DUD was usually preceded by the 'other' mental disorder. Substantial cross-national differences in DUD prevalence were found, reflecting myriad social, environmental, legal and other influences. Nonetheless, patterns of course and correlates of DUDs were strikingly consistent. These findings provide foundational data on country-level comparisons of DUDs.

Sections du résumé

BACKGROUND
Illicit drug use and associated disease burden are estimated to have increased over the past few decades, but large gaps remain in our knowledge of the extent of use of these drugs, and especially the extent of problem or dependent use, hampering confident cross-national comparisons. The World Mental Health (WMH) Surveys Initiative involves a standardised method for assessing mental and substance use disorders via structured diagnostic interviews in representative community samples of adults. We conducted cross-national comparisons of the prevalence and correlates of drug use disorders (DUDs) in countries of varied economic, social and cultural nature.
METHODS AND FINDINGS
DSM-IV DUDs were assessed in 27 WMH surveys in 25 countries. Across surveys, the prevalence of lifetime DUD was 3.5%, 0.7% in the past year. Lifetime DUD prevalence increased with country income: 0.9% in low/lower-middle income countries, 2.5% in upper-middle income countries, 4.8% in high-income countries. Significant differences in 12-month prevalence of DUDs were found across country in income groups in the entire cohort, but not when limited to users. DUDs were more common among men than women and younger than older respondents. Among those with a DUD and at least one other mental disorder, onset of the DUD was usually preceded by the 'other' mental disorder.
CONCLUSIONS
Substantial cross-national differences in DUD prevalence were found, reflecting myriad social, environmental, legal and other influences. Nonetheless, patterns of course and correlates of DUDs were strikingly consistent. These findings provide foundational data on country-level comparisons of DUDs.

Identifiants

pubmed: 31255918
pii: S0955-3959(19)30055-6
doi: 10.1016/j.drugpo.2019.03.002
pmc: PMC7370948
mid: NIHMS1602019
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

103-112

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA016558
Pays : United States
Organisme : FIC NIH HHS
ID : R03 TW006481
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH069864
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH061905
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH060220
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH070884
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA044170
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH059575
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIMH NIH HHS
ID : R13 MH066849
Pays : United States

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Références

Curr Opin Psychiatry. 2007 Jul;20(4):393-7
pubmed: 17551355
Drug Alcohol Depend. 2011 Sep 1;117(2-3):85-101
pubmed: 21377813
Clin Psychol Rev. 2018 Dec;66:12-23
pubmed: 29174306
BMC Public Health. 2010 Mar 23;10:152
pubmed: 20331880
PLoS Med. 2008 Jul 1;5(7):e141
pubmed: 18597549
Addiction. 1999 Oct;94(10):1541-50
pubmed: 10790906
Lancet Psychiatry. 2016 Jul;3(7):673-84
pubmed: 27371989
Drug Alcohol Depend. 2007 Nov 2;91(1):1-9
pubmed: 17570618
Alcohol Clin Exp Res. 2016 Aug;40(8):1728-36
pubmed: 27426631
Lancet. 2013 Nov 9;382(9904):1564-74
pubmed: 23993281
Addiction. 2008 Jul;103(7):1057-9
pubmed: 18554338
Int J Methods Psychiatr Res. 2017 Sep;26(3):
pubmed: 28211594
Addiction. 2015 Jan;110(1):19-35
pubmed: 25287883
World Psychiatry. 2017 Oct;16(3):299-307
pubmed: 28941090
Drug Alcohol Depend. 2006 Sep;84 Suppl 1:S85-93
pubmed: 16769182
Addiction. 2009 Aug;104(8):1346-55
pubmed: 19549055
Am J Psychiatry. 1986 Apr;143(4):463-8
pubmed: 3953889

Auteurs

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre (NDARC), UNSW Sydney, Sydney, Australia. Electronic address: l.degenhardt@unsw.edu.au.

Chrianna Bharat (C)

National Drug and Alcohol Research Centre (NDARC), UNSW Sydney, Sydney, Australia.

Meyer D Glantz (MD)

Department of Epidemiology, Services, and Prevention Research (DESPR), National Institute on Drug Abuse (NIDA), National Institute of Health (NIH), Bethesda, MD, USA.

Nancy A Sampson (NA)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Kate Scott (K)

Department of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand.

Carmen C W Lim (CCW)

Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Queensland, Australia; Queensland Brain Institute, University of Queensland, St Lucia, Queensland, Australia.

Sergio Aguilar-Gaxiola (S)

Center for Reducing Health Disparities, UC Davis Health System, Sacramento, CA, USA.

Ali Al-Hamzawi (A)

College of Medicine, Al-Qadisiya University, Diwaniya governorate, Iraq.

Jordi Alonso (J)

Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Pompeu Fabra University (UPF), Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Laura H Andrade (LH)

Núcleo de Epidemiologia Psiquiátrica - LIM 23, Instituto de Psiquiatria Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.

Evelyn J Bromet (EJ)

Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, New York, USA.

Ronny Bruffaerts (R)

Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium.

Brendan Bunting (B)

School of Psychology, Ulster University, Londonderry, United Kingdom.

Giovanni de Girolamo (G)

IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Oye Gureje (O)

Department of Psychiatry, University College Hospital, Ibadan, Nigeria.

Josep Maria Haro (JM)

Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.

Meredith G Harris (MG)

Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Queensland, Australia; School of Public Health, The University of Queensland, QLD, Australia.

Yanling He (Y)

Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

Peter de Jonge (P)

Developmental Psychology, Department of Psychology, Rijksuniversiteit Groningen, Groningen, The Netherlands; Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands.

Elie G Karam (EG)

Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon; Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon; Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon.

Georges E Karam (GE)

Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon; Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Balamand University, Faculty of Medicine, Beirut, Lebanon.

Andrzej Kiejna (A)

Wroclaw Medical University, Wroclaw, Poland; University of Lower Silesia, Wroclaw, Poland.

Sing Lee (S)

Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong.

Jean-Pierre Lepine (JP)

Hôpital Lariboisière- Fernand Widal, Assistance Publique Hôpitaux de Paris, Paris, France; Universités Paris Descartes-Paris Diderot, Paris, France; Institut National de la Sante et de la Recherche Medicale (INSERM) UMR-S 1144, Paris, France.

Daphna Levinson (D)

Mental Health Services, Ministry of Health, Jerusalem, Israel.

Victor Makanjuola (V)

Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria; University College Hospital, Ibadan, Nigeria.

Maria Elena Medina-Mora (ME)

National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico.

Zeina Mneimneh (Z)

Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA.

Fernando Navarro-Mateu (F)

Unidad de Docencia, Investigación y Formación en Salud Mental (UDIF-SM), Servicio Murciano de Salud, Murcia, Spain; IMIB-Arrixaca, Murcia, Spain; CIBER de Epidemiología y Salud Pública (CIBERESP), Murcia, Spain.

José Posada-Villa (J)

Colegio Mayor de Cundinamarca University, Faculty of Social Sciences, Bogota, Colombia.

Dan J Stein (DJ)

Department of Psychiatry & Mental Health and South African Medical Council Research Unit on Risk and Resilience in Mental Disorders, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.

Hisateru Tachimori (H)

National Institute of Mental Health, National Center for Neurology and Psychiatry, Kodaira, Tokyo, Japan.

Yolanda Torres (Y)

Center for Excellence on Research in Mental Health, CES University, Medellin, Colombia.

Zahari Zarkov (Z)

Directorate Mental Health, National Center of Public Health and Analyses, Sofia, Bulgaria.

Somnath Chatterji (S)

Department of Information, Evidence and Research, World Health Organization, Geneva, Switzerland.

Ronald C Kessler (RC)

Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH